| Mark A Pitner, MD | |
|
222 N 192nd St, Elkhorn, NE 68022-5363 | |
| (402) 390-4111 | |
| (402) 390-4115 |
| Full Name | Mark A Pitner |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 37 Years |
| Location | 222 N 192nd St, Elkhorn, Nebraska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578595682 | NPI | - | NPPES |
| 1578595682 | Medicaid | IA | |
| 47068731742 | Medicaid | NE | |
| 47068731751 | Medicaid | NE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | 29076 (Iowa) | Secondary |
| 207X00000X | Orthopaedic Surgery | 18613 (Nebraska) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kindred At Home | Omaha, NE | Home health agency |
| The Nebraska Methodist Hospital | Omaha, NE | Hospital |
| Methodist Jennie Edmundson | Council bluffs, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Md West One, Pc | 0446228852 | 66 |
News Archive
In addition to their suffering, rare disease patients often have to face the harsh reality that few pharmaceutical companies will ever be able to offer new treatments for their condition because the costs of new treatments will never be recovered from such a small market. But there are ways they can be helped. The U.S. Food and Drug Administration's "Orphan Drug Designation" offers a wide range of benefits that help organizations developing treatments for diseases and conditions affecting fewer than 200,000 patients in the United States.
Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced that researchers who invented DSC127 have been awarded a $4.5 million, 16-month grant by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority to investigate preclinically the use of DSC127 in the treatment of skin injuries associated with acute radiation exposure.
A team at The Saban Research Institute of Children's Hospital Los Angeles has made crucial discoveries about the role of key proteins in wound healing in the tiny air sacs in the lungs known as "alveoli" that could lead to new therapies for children and adults.
Star Scientific, Inc. reports that it has successfully developed a moist snuff tobacco product that has extremely low levels of carcinogens - much lower than any snuff products currently in the marketplace. This new product has levels of tobacco-specific nitrosamines (TSNAs) - recognized by scientists worldwide as one of the most powerful cancer-causing agents in tobacco leaf and smoke - below 20 parts per billion (nanograms-per-gram moist weight, as used) in initial testing.
› Verified 5 days ago
| Entity Name | Physicians Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821049156 PECOS PAC ID: 4880506062 Enrollment ID: O20031105000345 |
News Archive
In addition to their suffering, rare disease patients often have to face the harsh reality that few pharmaceutical companies will ever be able to offer new treatments for their condition because the costs of new treatments will never be recovered from such a small market. But there are ways they can be helped. The U.S. Food and Drug Administration's "Orphan Drug Designation" offers a wide range of benefits that help organizations developing treatments for diseases and conditions affecting fewer than 200,000 patients in the United States.
Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced that researchers who invented DSC127 have been awarded a $4.5 million, 16-month grant by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority to investigate preclinically the use of DSC127 in the treatment of skin injuries associated with acute radiation exposure.
A team at The Saban Research Institute of Children's Hospital Los Angeles has made crucial discoveries about the role of key proteins in wound healing in the tiny air sacs in the lungs known as "alveoli" that could lead to new therapies for children and adults.
Star Scientific, Inc. reports that it has successfully developed a moist snuff tobacco product that has extremely low levels of carcinogens - much lower than any snuff products currently in the marketplace. This new product has levels of tobacco-specific nitrosamines (TSNAs) - recognized by scientists worldwide as one of the most powerful cancer-causing agents in tobacco leaf and smoke - below 20 parts per billion (nanograms-per-gram moist weight, as used) in initial testing.
› Verified 5 days ago
| Entity Name | Md West One, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588616767 PECOS PAC ID: 0446228852 Enrollment ID: O20050221000184 |
News Archive
In addition to their suffering, rare disease patients often have to face the harsh reality that few pharmaceutical companies will ever be able to offer new treatments for their condition because the costs of new treatments will never be recovered from such a small market. But there are ways they can be helped. The U.S. Food and Drug Administration's "Orphan Drug Designation" offers a wide range of benefits that help organizations developing treatments for diseases and conditions affecting fewer than 200,000 patients in the United States.
Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced that researchers who invented DSC127 have been awarded a $4.5 million, 16-month grant by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority to investigate preclinically the use of DSC127 in the treatment of skin injuries associated with acute radiation exposure.
A team at The Saban Research Institute of Children's Hospital Los Angeles has made crucial discoveries about the role of key proteins in wound healing in the tiny air sacs in the lungs known as "alveoli" that could lead to new therapies for children and adults.
Star Scientific, Inc. reports that it has successfully developed a moist snuff tobacco product that has extremely low levels of carcinogens - much lower than any snuff products currently in the marketplace. This new product has levels of tobacco-specific nitrosamines (TSNAs) - recognized by scientists worldwide as one of the most powerful cancer-causing agents in tobacco leaf and smoke - below 20 parts per billion (nanograms-per-gram moist weight, as used) in initial testing.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark A Pitner, MD 8005 Farnam Dr Ste 305, Omaha, NE 68114-3426 Ph: (402) 390-4111 | Mark A Pitner, MD 222 N 192nd St, Elkhorn, NE 68022-5363 Ph: (402) 390-4111 |
News Archive
In addition to their suffering, rare disease patients often have to face the harsh reality that few pharmaceutical companies will ever be able to offer new treatments for their condition because the costs of new treatments will never be recovered from such a small market. But there are ways they can be helped. The U.S. Food and Drug Administration's "Orphan Drug Designation" offers a wide range of benefits that help organizations developing treatments for diseases and conditions affecting fewer than 200,000 patients in the United States.
Derma Sciences, Inc., a medical device and pharmaceutical company focused on advanced wound care, today announced that researchers who invented DSC127 have been awarded a $4.5 million, 16-month grant by the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority to investigate preclinically the use of DSC127 in the treatment of skin injuries associated with acute radiation exposure.
A team at The Saban Research Institute of Children's Hospital Los Angeles has made crucial discoveries about the role of key proteins in wound healing in the tiny air sacs in the lungs known as "alveoli" that could lead to new therapies for children and adults.
Star Scientific, Inc. reports that it has successfully developed a moist snuff tobacco product that has extremely low levels of carcinogens - much lower than any snuff products currently in the marketplace. This new product has levels of tobacco-specific nitrosamines (TSNAs) - recognized by scientists worldwide as one of the most powerful cancer-causing agents in tobacco leaf and smoke - below 20 parts per billion (nanograms-per-gram moist weight, as used) in initial testing.
› Verified 5 days ago
Kayvon Izadi, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 222 N 192nd St, Elkhorn, NE 68022 Phone: 402-390-4111 Fax: 402-390-4115 | |
Dr. Justin Lee Makovicka, M.D. Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 222 N 192nd St, Elkhorn, NE 68022 Phone: 402-390-4111 Fax: 402-390-4115 | |
Dr. Jon Charles Uggen, D.O. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 222 N 192nd St, Elkhorn, NE 68022 Phone: 402-390-4111 Fax: 402-390-4115 | |
Michael Anthony Delcore, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 222 N 192nd St, Elkhorn, NE 68022 Phone: 402-390-4111 Fax: 402-390-4115 | |
Kathleen Marie Grier, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 222 N 192nd St Ste 305, Elkhorn, NE 68022 Phone: 402-390-4111 Fax: 402-390-4115 | |
Dr. Hsueh-yu Wesley Cheng, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 222 N 192nd St, Elkhorn, NE 68022 Phone: 402-390-4111 Fax: 402-390-4115 |